Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 9, Issue 7, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac279
Keywords
HIV; liver biopsy; liver fibrosis; liver steatosis; noninvasive markers
Categories
Funding
- Instituto de Salud Carlos III (ISCIII) [PI17/01218]
- Plan Nacional R + D+ I.
Ask authors/readers for more resources
Ultrasound and controlled attenuation parameter perform best in diagnosing liver steatosis in persons with HIV, while fatty liver index, TyG, and hepatic steatosis index also show good performance. It is recommended to use TyG or FLI as the first test and ultrasound or CAP as the second test to accurately diagnose or exclude NAFLD.
Background Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis of NAFLD in PWH. Methods This is a cross-sectional study of PWH on stable antiretroviral therapy with persistently elevated transaminases and no known liver disease. The area under the receiver operating characteristic curve (AUROC) was calculated to compare the diagnostic accuracy of liver biopsy with abdominal ultrasound, transient elastography (TE) (including controlled attenuation parameter [CAP]), and noninvasive markers of steatosis (triglyceride and glucose index [TyG], hepatic steatosis index [HSI], fatty liver index [FLI]) and fibrosis ([FIB]-4, aminotransferase-to-platelet ratio index [APRI], NAFLD fibrosis score). We developed a diagnostic algorithm with serial combinations of markers. Results Of 146 patients with increased transaminase levels, 69 underwent liver biopsy (90% steatosis, 61% steatohepatitis, and 4% F >= 3). The AUROC for steatosis was as follows: ultrasound, 0.90 (0.75-1); CAP, 0.94 (0.88-1); FLI, 0.81 (0.58-1); HSI, 0.74 (0.62-0.87); and TyG, 0.75 (0.49-1). For liver fibrosis >= F3, the AUROC for TE, APRI, FIB-4, and NAFLD fibrosis score was 0.92 (0.82-1), 0.96 (0.90-1), 0.97 (0.93-1), and 0.85 (0.68-1). Optimal diagnostic performance for liver steatosis was for 2 noninvasive combined models of tests with TyG and FLI/HSI as the first tests and ultrasound or CAP as the second tests: AUROC = 0.99 (0.97-1, P < .001) and 0.92 (0.77-1, P < .001). Conclusions Ultrasound and CAP performed best in diagnosing liver steatosis, and FLI, TyG, and HSI performed well. We propose an easy-to-implement algorithm with TyG or FLI as the first test and ultrasound or CAP as the second test to accurately diagnose or exclude NAFLD. An easy-to-implement algorithm diminishes diagnostic uncertainty and the likelihood of diagnostic errors, thus eventually reducing the need for liver biopsy. Ultrasound and controlled attenuation parameter perform very well in diagnosing liver steatosis in persons with HIV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available